May 10, 2021

A new artificial intelligence algorithm can predict risk for age-related macular degeneration (AMD), according to a study published in the April issue of Translational Vision Science and Technology. Alauddin Bhuiyan, Ph.D., from iHealthScreen Inc. in New York City, and colleagues used 116,875 color fundus photos from 4,139 participants of the Age-related Eye Disease Study to...

Dealing with diversity and adequate representation in Alzheimer’s Disease clinical trials is especially pressing due to the large number of individuals with this disease and the very high failure rate (99.6%) of new drugs. This literature review, published in the Journal of Alzheimer’s Disease, analyzes the racial and sex-based disparities in Alzheimer’s clinical trials over...

Under-enrollment in clinical trials can significantly impact the development of appropriate treatment options, reducing the validity of researched outcomes. In many cases, it can also result in the early termination of the research studies themselves. This study, published in the Journal of Neuro-Oncology, analyzes the impact of race/ethnicity and socioeconomic status on enrollment rates in...

Randomized clinical trials are an essential component of the development and proper deployment of novel therapies. However, there are many disparities in access to and participation in clinical trials throughout the United States. Moreover, the COVID-19 pandemic has resulted in large-scale destabilization, which has extended to clinical trials. This article, published in Ethnicity & Disease,...

As a result of the COVID-19 pandemic, clinical trials have been put in a very complex position. The standard ways that many clinical trials are run are difficult to maintain with strained access to supplies, destabilized schedules, and additional health regulations. This article, published in Gynecologic Oncology, provides an analysis of best practices for conducting...

Patient participation rates in clinical trials can directly impact future patient outcomes, as high enrollment is necessary for understanding the effects of novel therapies. In addition to sheer enrollment numbers, clinical trial enrollment must also adequately represent the population in terms of race, age, and other factors. Unfortunately, there are currently significant disparities in cancer...

https://fast.wistia.net/embed/iframe/blateobmza

Former NBA player Christopher Gandy talks about AI algorithms Issue-98

A talk with former NBA player Christopher Gandy Artificial intelligence has been around for several decades, but its element of deep learning – using algorithms to model high-brow abstractions from a constant stream of connected data inputs – is already having an impact in the insurance and financial legacy industry. There are plenty of sources...